According to a previous report by Tolaney et al., reported in a single-group, uncontrolled trial examining the efficacy of adjuvant paclitaxel and trastuzumab for stage T1-2 HER2- positive breast cancer (37). This evidence concerns the gene ERBB2 and breast cancer.